At a glance

ClinicalIndex Comparison Record

N/ACompleted· 35 enrolled

Drug / intervention

any closed-loop automatic insulin delivery system (or artificial pancreas) European Conformity (CE)-markingdevice

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04635280

NCT04635280N/ACompleted

Compare CT.gov

Evaluation of Satisfaction Regarding Home Healthcare Provider (HHP) Management of Type 1 Diabetic Patients Equipped With the "Closed-loop" Automated Insulin Delivery System (or "Artificial Pancreas"), Under Normal Conditions of Use

Air Liquide Santé International·interventional·Posted Nov 19, 2020·Updated Oct 15, 2024

In Brief

A clinical study evaluating any closed-loop automatic insulin delivery system (or artificial pancreas) European Conformity (CE)-marking for Diabetes type1. Completed, enrolled 35 participants across 2 sites.

Detailed Summary

SATURN study aims at evaluating Home Healthcare Provider (HHP) Management of type 1 diabetic patients using a closed-loop automatic insulin delivery system (or artificial pancreas), and specifically satisfaction and interactions of all people involved (patients, HHPs, hospital healthcare teams) after 1 and 3 months of follow-up, under normal conditions of use.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsDiabetes type1

CountriesFrance

Collaborators--

Timeline

N/ACompletedFinished

202120222023202420252026

First PostedNov 2020

Enrollment StartMay 2021

Primary CompletionJan 2022

TodayJul 2026

First PostedNov 19, 2020

Enrollment StartMay 10, 2021

Primary CompletionJan 12, 2022

TodayJul 2, 2026

Enrollment to primary: 8 monthsPosted 5.6 years ago

Interventions

any closed-loop automatic insulin delivery system (or artificial pancreas) European Conformity (CE)-markingdevice

A closed-loop automatic insulin delivery system includes a combination of an insulin pump, a continuous glucose monitoring system and an algorithm.